share_log

泽璟制药(688266.SH):注射用ZG005与盐酸吉卡昔替尼片联合用药获得药物临床试验批准通知书

Zejing Pharmaceutical (688266.SH): The injection ZG005 combined with hydrochloride giptanib tablets has received the notice of approval for drug clinical trials.

Gelonghui Finance ·  Dec 25 16:29

On December 25, Gelonghui reported that Zegeng Pharmaceutical (688266.SH) announced that it recently received the "Approval Notice for Clinical Trials of Pharmaceuticals" issued by the National Medical Products Administration, approving the clinical trials of injectable ZG005 combined with hydrochloride gicaxetine tablets for advanced solid tumors and refractory relapsed lymphoma.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment